As a CDMO, CdmoGen must be flexible, reliable, and able to smoothly scale up manufacturing and transfer technology.
In addition, the world industry is moving quickly. Recently, the development of new drugs in the field of ex vivo gene therapy that complements the strengths and weaknesses of gene therapy and cell therapy has been rapidly increasing. In addition, the development of CAR-T, a customized cancer treatment that has been approved by the US FDA one after another, is rapidly increasing around the world. CdmoGen must therefore be able to rapidly satisfy needs from customers worldwide.
CdmoGen Co., Ltd is the only company in South Korea offering GMP manufacturing technology and manufacturing facility specialized in virus-based vaccines and gene therapy drugs. We therefore satisfy the needs of companies developing new drugs.
As a specialized CMO company with global reach and specific technology needs from its customers, CdmoGen has implemented filling processes using the Crystal® M1 Filling Line and several sizes of the AT-Closed Vial® to meet the evolving demand. Aseptic Technologies’ Filling Lines allow for scalability and flexibility of the processes; and enable CdmoGen’s experienced staff to adapt to evolving requirements.
CdmoGen values Aseptic Technologies’ expertise in aseptic filling, and the services that come with our products.
"Aseptic Technologies vials are well suited for Ex Vivo Gene & Cell Therapy applications: they provide the quality standards for final filling DP products.
The closed filling process provides greater sterility assurance and needs no cleaning and sterilization of the AT-Closed Vial®.
Aseptic Technologies also offers efficient installation, commissioning and validation services and assistance.”